Insider Transactions
| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 13, 2015 | SVP, GM - Oncology | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 18,100 | -- | -- | |
| Feb 03, 2020 | EVP, General Counsel and CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 18,204 | -- | 18,204 | |
| Aug 06, 2013 | Director, President and Chief Executive | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 18,388 | -- | 76,551 | |
| Jul 22, 2015 | EVP and CCO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 18,617 | -- | 18,617 | |
| Jul 20, 2022 | EVP and CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 18,650 | -- | 18,650 | |
| Feb 07, 2005 | VP - Operations | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 18,873 | $4.35 | 18,873 | |
| Feb 07, 2005 | VP - Operations | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 18,873 | -- | 25,000 | |
| Jul 25, 2014 | EVP and CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 18,901 | -- | 18,901 | |
| Mar 23, 2006 | Director | Form 4 | Open market or private sale of non-derivative or derivative security | 19,000 | $29.00 | 349,142 | |
| Feb 07, 2005 | VP - Regulatory Affairs | Form 4 | Open market or private sale of non-derivative or derivative security | 19,091 | $20.40 | 3,855 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.